Morning Overview on MSN
A Harvard scientist says his team is preparing the first human trials aimed at reversing aging
A team linked to Harvard Medical School has dosed the first patient in a clinical trial designed to reverse cellular aging in the human eye. The study, called ER-100, uses a gene therapy vector to ...
Nearly 90 years after Ugo Cerletti and Lucio Bini introduced electroconvulsive therapy (ECT), brain stimulation therapies ...
Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary ...
Nearly 90 years after Ugo Cerletti and Lucio Bini introduced electroconvulsive therapy (ECT), brain stimulation therapies ...
To accomplish this, the plant relies on two groups of proteins that silence gene expression: the Polycomb repressive complexes PRC1 and PRC2. These complexes modify the structure of chromatin—the DNA ...
Gram-stained section of a macrophage with ingested S epidermidis bacteria, seen as purple granules within its cytoplasm. In this stain, the nucleus appears pale, with a reddish nucleolus. It is ...
For more than 30 years, scientists have studied how the myogenic determination gene number 1 (MYOD) protein binds DNA to modify the gene expression of muscle stem cells. Similar to the instant kung fu ...
Scientists at the MRC Laboratory of Medical Sciences (LMS) have discovered a DNA-based “dimmer switch” that regulates the activity of a critical developmental gene, Cdx2. This work could pave the way ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results